- A majority of Canadian cannabis users identified quality and safety as top factors in choosing where to purchase cannabis
- Canada’s Shoppers Drug Mart is now the exclusive direct-to-patient online provider of FlowrRx products
- Flowr grows premium cannabis with a goal of non-irradiation using production methods that are expected to generate high crop yields at low operating costs
Medicinal cannabis patients in Canada are rightly concerned about how cannabis products prescribed by their physicians are produced. According to Canada’s national statistical agency, Statistics Canada, 76 percent of medical cannabis patients responding to the Q4 2018 ‘National Cannabis Survey’ identified quality and safety as the top factors used in their decision-making process when choosing where to fill their prescriptions (http://ibn.fm/yRfzw).
The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, cultivates its cannabis in a purpose-built facility with controlled environments engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. Control over cultivation and innovative practices result in a cost-efficient cultivation process. As the company notes, high yields per square foot are key to ensuring low operating costs and profitability.
Flowr aims to avoid irradiating its final product, something that approximately 80 percent of other cannabis companies do, according to Cannabis Tech (http://ibn.fm/gRISH). Flowr’s commitment to delivering a clean cannabis product that meets Health Canada’s strict testing requirements with a goal of no irradiation sets it apart, as CEO Vinay Tolia explained in a podcast (http://ibn.fm/ieuOV), noting that “the plant needs a lot of TLC.”
Medical cannabis patients can now purchase Flowr’s premium FlowrRx products through the Shoppers Drug Mart online medical cannabis platform, as the company recently announced in a news release (http://ibn.fm/juq7F). This direct-to-patient distribution agreement with Shoppers Drug Mart provides medical cannabis patients with several options.
“Flowr’s premium medical cannabis is grown in what we believe is the industry’s most advanced GMP designed cultivation facility. This relationship is testament to our commitment to ultra-high-quality cannabis cultivation and further solidifies Flowr’s role in Canada’s medical cannabis landscape,” Tolia said in the news release.
Canada opened up recreational cannabis to adult users in October 2018 and has since released new regulations governing cannabis-infused edibles and beverages, along with cannabis concentrates, which are set to be legalized in mid-October 2019. According to Stratistics MRC, the global cannabis market accounted for $10.39 billion in 2017 sales and is expected to reach $154.82 billion by 2026, growing at a compound annual growth rate of 35 percent during the forecast period (http://ibn.fm/bpoFd).
For more information, visit the company’s website at www.Flowr.ca
NOTE TO INVESTORS: The latest news and updates relating to FLPWF are available in the company’s newsroom at http://ibn.fm/FLWPF